Virios Therapeutics (NASDAQ:VIRI – Get Free Report) and Xencor (NASDAQ:XNCR – Get Free Report) are both small-cap medical devices companies, but which stock is better? We’ll compare the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends, and earnings.

Profitability

This table compares the net margins, return on equity and return on assets of Virios Therapeutics and Xencor.

Volatility and risk

Virios Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. For comparison, Xencor has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Insider and institutional ownership

9.1% of Virios Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. In comparison, 5.2% of Xencor shares are held by insiders. Strong institutional ownership is an indication that large asset managers, foundations and hedge funds believe a company is poised for long-term growth.

Valuation and profit

This table compares the revenue, earnings per share (EPS), and valuation of Virios Therapeutics and Xencor.

Virios Therapeutics has higher profits but lower revenues than Xencor. Xencor trades at a lower price-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of the current ratings and recommendations for Virios Therapeutics and Xencor, as reported by MarketBeat.

Virios Therapeutics currently has a consensus target price of $0.60, suggesting a potential upside of 185.04%. Xencor has a consensus target price of $34.44, suggesting a potential upside of 94.93%. Given Virios Therapeutics’ higher potential upside, research analysts clearly believe Virios Therapeutics is more favorable than Xencor.

Summary

Virios Therapeutics beats Xencor on 8 of the 14 factors compared between the two stocks.

About Virios Therapeutics

(Get free report)

Virios Therapeutics, Inc., a development-stage biotechnology company, is focused on developing novel antiviral therapies to treat diseases associated with an abnormal immune response caused by viruses. The Company’s lead development candidate is IMC-1, a fixed-dose combination of famciclovir and celecoxib to treat fibromyalgia. The Company is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of fatigue, sleep, attention, pain, autonomic function and anxiety associated with long-COVID. The Company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The Company was founded in 2012 and is headquartered in Alpharetta, Georgia.

About Xencor

(Get free report)

Xencor, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of engineered monoclonal antibodies and cytokine therapies to treat patients with cancer and autoimmune diseases. The company offers Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It is developing Plamotamab, a bispecific antibody, which is in a Phase I clinical trial to treat non-Hodgkin lymphoma; and Vudalimab, a bispecific antibody, which is in a Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other types of solid tumors. The Company is also developing XmAb306, which is in a Phase I clinical trial to treat solid tumors; XmAb104, which is in a Phase II clinical trial to treat patients with select solid tumors; XmAb564, which is in a Phase Ia clinical trial for the treatment of autoimmune diseases; AMG 509, which is in a Phase I clinical trial for the treatment of prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662, which is in a Phase I clinical trial for the treatment of patients with solid tumors. Additionally, the Company is developing VIR-3434, which is in a Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482, which is in a Phase 2 clinical trial for the treatment of hepatitis B virus. The company is developing AIMab7195 to reduce blood serum levels of IgE, which mediates allergic reactions and allergic diseases; Obexelimab to treat autoimmune diseases; and Xpro1595 to treat patients with Alzheimer’s disease and depression. It has a licensing agreement with Caris Life Sciences. Xencor, Inc. was founded in 1997 and is headquartered in Pasadena, California.

Get daily news and reviews for Virios Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Virios Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.